One-Year Survival and Prognosticators of Adults With Acute Leukemia at the Uganda Cancer Institute.
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
medline:
31
7
2023
pubmed:
27
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
Acute leukemias are associated with substantial morbidity and mortality, particularly in the adult population. Despite an increasing burden of acute leukemia in developing countries, there are limited data on clinical outcomes and prognostic factors in this setting. In this study, we aimed to describe the clinical characteristics, survival, and prognostic factors of adults with acute leukemia at the Uganda Cancer Institute (UCI). A retrospective cohort study was conducted between January 2009 and December 2018, reviewing data of patients 18 years or older with a cytopathologic diagnosis of acute leukemia at UCI. Data were extracted on clinical and laboratory characteristics, response to treatment, and survival. Cox-proportional hazards regression and survival analysis were performed to determine survival rates and associated factors. In total, 233 participants were enrolled. Most (59.2%. n = 138) participants were male, with a median age of 32 years (IQR, 23-48 years), and 136 (58.4%) had AML. Overall, the 1-year survival was 16.5%, with a median survival time of 47 (IQR, 21-219) days. Predictors of mortality were being a female (adjusted hazard ratio [aHR], 2.8; 95% CI, 1.2 to 6.7; Patients with acute leukemia in Uganda have poor overall survival. Prospective studies are recommended to better understand causes of early mortality.
Identifiants
pubmed: 37499182
doi: 10.1200/GO.22.00244
pmc: PMC10581653
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200244Références
J Glob Oncol. 2018 Sep;4:1-12
pubmed: 30222028
Sci Rep. 2017 Dec 21;7(1):17998
pubmed: 29269861
Eur J Cancer. 2005 Jul;41(11):1570-83
pubmed: 16026693
Iran J Pathol. 2017 Summer;12(3):265-271
pubmed: 29531552
J Clin Oncol. 2017 Nov 10;35(32):3678-3687
pubmed: 28892433
BMJ. 1989 Oct 28;299(6707):1069-72
pubmed: 2511967
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Bone Marrow Transplant. 2012 Feb;47(2):212-6
pubmed: 21423123
BMC Palliat Care. 2011 Sep 21;10:14
pubmed: 21936940
J Pediatr Hematol Oncol. 2013 Oct;35(7):573-6
pubmed: 23929316
Am J Manag Care. 2018 Aug;24(16 Suppl):S347-S355
pubmed: 30132678
Haematologica. 2013 Feb;98(2):222-9
pubmed: 22929974
Int J Cancer. 2014 Jul 15;135(2):432-9
pubmed: 24615279
Hematol Transfus Cell Ther. 2022 Dec 5;:
pubmed: 36564332
Leukemia. 1993 Aug;7 Suppl 2:S138-41
pubmed: 8361219
J Clin Oncol. 2012 Dec 20;30(36):4515-23
pubmed: 22987078
Am J Clin Oncol. 2011 Jun;34(3):297-304
pubmed: 20562587
J Egypt Natl Canc Inst. 2007 Jun;19(2):106-13
pubmed: 19034340
Eur J Cancer. 2017 Oct;84:130-140
pubmed: 28802709
Arch Pathol Lab Med. 2011 Feb;135(2):191-3
pubmed: 21284436
Arch Pathol Lab Med. 2011 Feb;135(2):183-6
pubmed: 21284434
Eur J Haematol. 2020 Mar;104(3):162-169
pubmed: 31724208
J Pak Med Assoc. 2002 Oct;52(10):482-6
pubmed: 12553679
Lancet Oncol. 2013 Apr;14(4):e142-51
pubmed: 23561745
J Clin Med. 2016 Mar 05;5(3):
pubmed: 26959069
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241148
Leukemia. 2015 Mar;29(3):548-55
pubmed: 25092141
J Drug Assess. 2018 Jul 10;7(1):51-53
pubmed: 30034924
BMJ Open. 2017 Oct 5;7(10):e017052
pubmed: 28982824
N Engl J Med. 2006 Jan 12;354(2):166-78
pubmed: 16407512
Br J Haematol. 2015 Jul;170(1):110-7
pubmed: 25858293
Pediatr Blood Cancer. 2023 Nov;70(11):e28087
pubmed: 31774234
Oncotarget. 2016 Nov 1;7(44):72044-72056
pubmed: 27732947
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Anticancer Res. 2019 Apr;39(4):1899-1906
pubmed: 30952731
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896